PACLITAXEL
Manufacturer: American Regent, Inc.
Score: 141.0
Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) is a microtubule inhibitor used for the treatment of metastatic breast cancer, non-small cell lung cancer, and adenocarcinoma of the pancreas. The drug has a boxed warning for severe myelosuppression and is contraindicated in patients with baseline neutrophil counts of less than 1,500 cells/mm^3 or a history of severe hypersensitivity reactions to the drug. The recommended dosages vary by condition, with 260 mg/m^2 every 3 weeks for metastatic breast cancer, 100 mg/m^2 on Days 1, 8, and 15 of each 21-day cycle for non-small cell lung cancer, and 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle for adenocarcinoma of the pancreas. Special population considerations include use during pregnancy, nursing mothers, pediatric use, and geriatric use.
Severe myelosuppression
Dose reductions or discontinuation may be needed based on severe hematologic, neurologic, cutaneous, or gastrointestinal toxicities.
260 mg/m^2 every 3 weeks
Not established
100 mg/m^2 on Days 1, 8, and 15 of each 21-day cycle
Not established
125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle
Not established